Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TD-1792 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TD-1792 | EXPERIMENTAL | - |
| Vancomycin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TD-1792 | DRUG | TD-1792 2 mg/kg/day IV |
| Vancomycin | DRUG | Vancomycin 1 Gm IV q 12 hrs |
Inclusion Criteria: * major abscess requiring surgical incision and drainage,infected burn, deep/extensive cellulitis, infected ulcer, wound infections * requires at least 7 days of intravenous antibiotic treatment Exclusion Criteria: * more than 24 hours of antibiotic therapy * moderate or sever...
TD-1792 is an investigational small molecule being developed for the treatment of Staphylococcal Skin Infection, a type of complicated skin and skin structure infection caused by Gram-positive bacteria. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
TD-1792 is being developed by Theravance Biopharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TBPH. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with staphylococcal skin infections.
TD-1792 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and effectiveness for treating staphylococcal skin infections.
TD-1792 has been studied in one completed Phase 2 clinical trial, identified as NCT00442832. This randomized, double-blind, active-controlled trial enrolled 203 adult participants in the United States and evaluated the drug in patients with Gram-positive complicated skin and skin structure infections, including staphylococcal skin infections.
No, TD-1792 is not the same as vancomycin. TD-1792 is a distinct investigational small molecule developed by Theravance Biopharma. In its Phase 2 clinical trial, vancomycin was used as an active comparator, meaning the trial compared TD-1792 against vancomycin to evaluate its relative safety and efficacy.